Press Releases Items Per Page 102550 Year None202320222021202020192018201720162015201420132012201120102007 02.28.22 Syndax Announces Participation at Two Upcoming Investor Conferences 02.22.22 Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022 02.03.22 Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development 01.20.22 Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference 01.07.22 Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference 12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia 12.20.21 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares 12.15.21 Syndax Announces Pricing of $75.3 Million Public Offering 12.15.21 Syndax Announces Proposed Public Offering of Common Stock 12.13.21 Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 12.11.21 Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease 12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
02.22.22 Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022
02.03.22 Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development
12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia
12.20.21 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
12.13.21 Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
12.11.21 Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab
